Table 1. Clinical characteristics of HIV−TB+ individuals (n = 20).
| Clinical presentation of TB | Outcome | ||||||
| HIV−TB+ | Gender | Age at enrolment(years) | Culture at enrolment | Xraya | BMI | Culture at 26 weeks | Time of Conversion (wks)b |
| TB122 | F | 27 | + | 3 | 22.03 | − | 6 |
| TB036 | M | 46 | + | 2 | 18.29 | − | 8 |
| TB117 | M | 42 | + | 2 | 17.80 | − | 8 |
| TB131 | M | 44 | + | 2 | 19.61 | − | 8 |
| TB132 | M | 30 | + | 2 | 21.08 | − | 8 |
| TB039 | M | 56 | + | 2 | 21.34 | − | 12 |
| TB048 | M | 40 | + | 3 | 16.96 | − | 12 |
| TB095 | M | 48 | + | 3 | 18.13 | − | 12 |
| TB112 | F | 41 | + | 2 | 19.66 | − | 12 |
| TB124 | M | 62 | + | 3 | 26.77 | − | 12 |
| TB130 | M | 22 | + | 3 | 18.56 | − | 12 |
| TB088 | M | 21 | + | 2 | 18.78 | − | 24 |
| TB096 | M | 59 | + | 3 | 16.22 | − | 24 |
| TB114 | M | 26 | + | 2 | 17.10 | − | 24 |
| TB129 | M | 32 | + | 2 | 25.10 | − | 24 |
| TB097 | M | 52 | + | 2 | 17.51 | − | 24 |
| TB125 | M | 30 | + | 2 | 19.47 | + | 36 |
| TB069 | M | 37 | + | 3 | 17.01 | + | 52 |
| TB090 | M | 35 | + | 2 | 18.56 | − | 52 |
| TB031 | F | 50 | + | 2 | 24.12 | + | 52 |
| Average | (M) 86% | 40 | (+) 100% | 19.7 | (+) 15% | 21.1 | |
| Range | [21–62] | [16.22–26.77] | [6]–[52] | ||||
M: Male, F: Female.
a
: 1: No cavities ; 2: cavities <4 cm ; 3: cavities ≥4 cm.
BMI: Body mass index.
nd: not determined.
b
: The time of conversion is defined as the first analyzed time point where culture was negative and remained negative at all following time points. Studied individuals were divided into 3 groups according to the time of sputum culture conversion: ≤ 8 weeks, between 12 and 26 weeks and > 26 weeks after the initiation of TB therapy.